GSK
2 years ago ⋅ English ⋅ 5 min read
Newsroom
GSK presents promising new data for bepirovirsen, an investigational treatment for chronic hepatitis B

For media and investors onlyIssued: 25 June 2022, London UK- Interim analysis from the B-Clear phase IIb trial shows bepirovirsen’s potential to suppress both the surface antigen... Read More
GSK
2 years ago ⋅ English ⋅ 3 min read
Newsroom
GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries

GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countriesFor media and investors onlyIssued: 23 June 2022, London UK... Read More
GSK
2 years ago ⋅ English ⋅ 5 min read
Newsroom
GSK to present new data from the B-Clear phase IIb trial for bepirovirsen in chronic hepatitis B at the International Liver Congress 2022

For investors and media onlyFurther phase II data to be shared on linerixibat for cholestatic pruritus in primary biliary cholangitisGSK plc will present 12 abstracts at the European As... Read More
GSK
2 years ago ⋅ English ⋅ 2 min read
Newsroom
GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults

For investors and media onlyIssued: 10 June 2022, London UK - LSE announcement- First RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adult... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older

For investors and media only- Priorix becomes an additional source of measles, mumps and rubella vaccine for US patientsGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug... Read More
GSK
2 years ago ⋅ English ⋅ 14 min read
Newsroom
Update: Proposed demerger of the Consumer Healthcare business from GSK to form Haleon

For investors and media onlyOn 23 June 2021 at its Investor Update, GSK plc (“GSK” or the “Company”) confirmed its intention to separate its Consumer Healthcare... Read More